Symbol
| ASCL1
| contributors: mct/npt/pgu - updated : 06-05-2015
|
HGNC name
| achaete-scute complex homolog 1 (Drosophila)
|
HGNC id
| 738
|
corresponding disease(s)
|
CCHS4
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
|  
|  
| --low
|  
|
in differentiating neuroblastoma cells | tumoral
|  
|  
| --over
|  
|
in a majority of neuroblastoma tumors and cell lines | tumoral
|  
|  
| --over
|  
|
in progressive astrocytoma in 85.71 p100 of grade II diffuse astrocytoma, 90 p100 of grade III anaplastic astrocytoma | tumoral
|  
|  
| --over
|  
|
87.5 p100 of secondary glioblastoma multiforme | constitutional
|  
|  
|  
|  
|
results in hypoplasia of both the arcuate and ventromedial nuclei | tumoral
|  
|  
| --other
|  
|
constitutive expression in lung epithelium promotes remodeling through multiple pathways that are commonly activated during lung carcinogenesis | |
Susceptibility
|
to Parkinson disease (in association with PHOX2B) |
Variant & Polymorphism
repeat
| polyglutamine length variant with 13 repeats may exert a protective role for Parkinson disease in a Caucasian population |
|
|
Candidate gene
| for congenital hypoventilation syndrome (CCHS4) or modifier of PHOX2B |
Marker
Therapy target
| | |
| In Mash1-deficient mice, defects in thalamocortical axon pathfinding were found to be correlated with altered cell domain | |
mice lacking Ascl1 in the cerebellum have a major decrease in three types of interneurons with a tendency toward a loss of later-born interneurons, as well as an imbalance of oligodendrocytes and astrocytes |